Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Abstract 4127: Combined inhibition of RAF, MEK, and FAK attenuates melanoma brain metastases and prolongs survival in preclinical models

Karly A. Stanley, Jared D. Almazan, Tursun Turapov, David A. Kircher, Gennie L. Parkman, MiKaela N. Field, Katie M. Culver, Christopher M. Stehn, Silvia Coma, Jonathan A. Pachter, Howard Colman, Sheri L. Holmen

Cancer Res (2024) 84 (6_Supplement): 4127.

https://doi.org/10.1158/1538-7445.AM2024-4127

Published: 22 March 2024

View article titled, Abstract 4127: Combined inhibition of RAF, MEK, and FAK attenuates melanoma brain metastases and prolongs survival in preclinical models

Journal Articles

Abstract 2799: Pharmacodynamic biomarkers for TGFBR1 inhibition in oncology

Richard E. Heinz, Curtis A. Allred, David A. Kircher, Yuta Matsumura, Bettina Franz, Zhizhou Ye, Jinny Lee, Clifford J. Whatcott, Jason M. Foulks, Adam Siddiqui, Steven L. Warner

Cancer Res (2023) 83 (7_Supplement): 2799.

https://doi.org/10.1158/1538-7445.AM2023-2799

Published: 04 April 2023

View article titled, Abstract 2799: Pharmacodynamic biomarkers for TGFBR1 inhibition in oncology

Journal Articles

Abstract 5171: TP-6379, an investigational TGFBR1 inhibitor, shown to remodel the tumor microenvironment and enhance anti-tumorigenic immunological responses in syngeneic mouse models of cancer

David A. Kircher, Tetyana V. Forostyan, Richard E. Heinz, Curtis A. Allred, Sal Sommakia, Yuta Matsumura, Adam Siddiqui, Jason M. Foulks, Steven L. Warner

Cancer Res (2023) 83 (7_Supplement): 5171.

https://doi.org/10.1158/1538-7445.AM2023-5171

Published: 04 April 2023

View article titled, Abstract 5171: TP-6379, an investigational TGFBR1 inhibitor, shown to remodel the tumor microenvironment and enhance anti-tumorigenic immunological responses in syngeneic mouse models of cancer

Journal Articles

Abstract 2853: TP-6379, an investigational TGFBR1 inhibitor, shows improvement in survival and enhances activity of standard of care in preclinical ovarian cancer models

Tetyana V. Forostyan, David A. Kircher, Richard E. Heinz, Curtis Allred, Sal Sommakia, Yuta Matsumura, Adam Siddiqui, Jason M. Foulks, Steven L. Warner

Cancer Res (2023) 83 (7_Supplement): 2853.

https://doi.org/10.1158/1538-7445.AM2023-2853

Published: 04 April 2023

View article titled, Abstract 2853: TP-6379, an investigational TGFBR1 inhibitor, shows improvement in survival and enhances activity of standard of care in preclinical ovarian cancer models

Journal Articles

Abstract 2736: AKT1^E17K activates focal adhesion kinase and promotes melanoma brain metastasis

David A. Kircher, Kirby A. Trombetti, Mark R. Silvis, Gennie L. Parkman, Grant M. Fischer, Stephanie N. Angel, Christopher M. Stehn, Sean C. Strain, Allie H. Grossmann, Keith L. Duffy, Martin McMahon, Michael A. Davies, Michelle C. Mendoza, Matthew W. VanBrocklin, Sheri L. Holmen

Cancer Res (2020) 80 (16_Supplement): 2736.

https://doi.org/10.1158/1538-7445.AM2020-2736

Published: 15 August 2020

View article titled, Abstract 2736: AKT1<sup>E17K</sup> activates focal adhesion kinase and promotes melanoma brain metastasis

Journal Articles

The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State

Jae Hyuk Yoo, Samuel W. Brady, Lehi Acosta-Alvarez, Aaron Rogers, Jingfu Peng, Lise K. Sorensen, Roger K. Wolff, Tara Mleynek, Donghan Shin, Coulson P. Rich, David A. Kircher, Andrea Bild, Shannon J. Odelberg, Dean Y. Li, Sheri L. Holmen, Allie H. Grossmann

Cancer Res (2019) 79 (11): 2892–2908.

https://doi.org/10.1158/0008-5472.CAN-18-3026

Published: 03 June 2019

View article titled, The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State

Includes: Supplementary data

NARROW

Abstract 4127: Combined inhibition of RAF, MEK, and FAK attenuates melanoma brain metastases and prolongs survival in preclinical models

Abstract 2799: Pharmacodynamic biomarkers for TGFBR1 inhibition in oncology

Abstract 5171: TP-6379, an investigational TGFBR1 inhibitor, shown to remodel the tumor microenvironment and enhance anti-tumorigenic immunological responses in syngeneic mouse models of cancer

Abstract 2853: TP-6379, an investigational TGFBR1 inhibitor, shows improvement in survival and enhances activity of standard of care in preclinical ovarian cancer models

Abstract 2736: AKT1^E17K activates focal adhesion kinase and promotes melanoma brain metastasis

The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State

Email alerts

AACR Journals

Abstract 4127: Combined inhibition of RAF, MEK, and FAK attenuates melanoma brain metastases and prolongs survival in preclinical models

Abstract 2799: Pharmacodynamic biomarkers for TGFBR1 inhibition in oncology

Abstract 5171: TP-6379, an investigational TGFBR1 inhibitor, shown to remodel the tumor microenvironment and enhance anti-tumorigenic immunological responses in syngeneic mouse models of cancer

Abstract 2853: TP-6379, an investigational TGFBR1 inhibitor, shows improvement in survival and enhances activity of standard of care in preclinical ovarian cancer models

Abstract 2736: AKT1E17K activates focal adhesion kinase and promotes melanoma brain metastasis

The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Abstract 2736: AKT1^E17K activates focal adhesion kinase and promotes melanoma brain metastasis